Article Details

'Poorly designed': ICMR distances itself from BHU's study on Covaxin - BusinessToday

Retrieved on: 2024-05-20 19:52:19

Tags for this article:

Click the tags to see associated articles and topics

'Poorly designed': ICMR distances itself from BHU's study on Covaxin - BusinessToday. View article details on hiswai:

Summary

The article examines safety concerns related to Covaxin, a COVID vaccine developed by Bharat Biotech, as highlighted by a BHU study. ICMR criticized the study's design and dissociated itself from it, despite Bharat Biotech defending Covaxin's safety. The tags help contextualize the topic within India's pandemic response and vaccination efforts.

Article found on: www.businesstoday.in

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up